GenomicsbioRxivPreprint
Genetic evidence that the latency III stage of Epstein-Barr Virus infection is a therapeutic target for Multiple Sclerosis
Ali Afrasiabi, Grant Peter Parnell, Nicole Fewings…·David Richmond Booth
The paper identifies EBV latency III stage as a therapeutic target for MS by linking MS risk SNPs to EBV transcription factors and miRNAs.
1 citation